Domain To Bring First Wholly Owned GCPR Asset Into Clinic
After Building Reputation Through Partnerships
Executive Summary
The French firm is going it alone for the first time with a planned Phase I trial for its lead EP4 receptor antagonist in cancer after years of sharing its technology and GCPR expertise with big pharma.